/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | PPBTPURPLE BIOTECH LTD. |
|---|---|
| Last close | $1.34close 2026-11-09 |
| Change % | +2.29%close 2026-11-09 |
| Market cap | $1Mclose 2026-11-09 |
| P/E | no EPS filed |
| Revenue | no revenue filed |
| Rev growth (YoY) | no revenue filed |
| Net income | $18M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldProfitLoss As ofFY ending 2021-12-31 Filing20-F · 0001213900-22-011191 · filed 2022-03-09 Open the filing on EDGAR →Open the XBRL payload →CitePURPLE BIOTECH LTD. (PPBT), us-gaap:ProfitLoss: 17,826,000 USD, fiscal year ended 2021-12-31. Form 20-F, accession 0001213900-22-011191, filed 2022-03-09. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001614744/us-gaap/ProfitLoss.json |
| Net margin | not filed |
| EPS (diluted) | no EPS filed |
| Piotroski F-ScoreUNVALIDATED | not scored |
| Altman Z-ScoreUNVALIDATED | not scored |
| Beneish M-ScoreUNVALIDATED | not scored |
| Next earnings | — |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.